Shulman H M, McDonald G B, Matthews D, Doney K C, Kopecky K J, Gauvreau J M, Thomas E D
Gastroenterology. 1980 Dec;79(6):1178-91.
In order to assess the prevalence of venocclusive disease in autopsied recipients of bone marrow transplantation, we reviewed coded liver histology from 204 consecutive autopsied recipients transplanted for leukemia (142), other malignancies (5), or aplastic anemia (57). Twenty-seven patients with leukemia, 2 with carcinoma, and 3 with aplasia had venocclusive disease and survived 2-86 days post-transplant. Early lesions showed subintimal edema and hemorrhage within small central venules and centrilobular congestion with hepatocyte degeneration. Later lesions showed subtotal to complete fibrous obliteration of the central venule lumina and centrilobular sinusoidal fibrosis. Thirteen patients had a subclinical course, and 19 were symptomatic. Venocclusive disease was life-threatening or lethal in 13. Typical symptoms developed 1-3 wk post-transplant and consisted of sudden weight gain, hepatic enlargement, ascites, high bilirubin, and encephalopathy. Statistical analyses showed a significantly higher prevalence of venocclusive disease associated with transplantation for leukemia (P = 0.014), pretransplant conditioning with more rigorous chemoradiotherapy regimens (P < 0.001) and three- to fourfold increase of venocclusive disease in patients whose conditioning included dimethyl busulfan (P < 0.005). Abnormal liver tests before transplant were also more prevalent among patients with venocclusive disease. No factors predicted the clinical outcome of established venocclusive disease. Venocclusive disease showed no association with hepatic graft-versus-host disease even among prolonged cases with severe periportal hepatitis and cholestasis. Other centrilobular lesions (hepatocyte degeneration, sinusoidal fibrosis, and phlebosclerosis) were identified in 23 patients. These non-specific changes may occur with viral hepatitis, graft-versus-host disease or chemoradiotherapy effects.
为了评估骨髓移植尸检受者中肝静脉闭塞病的患病率,我们回顾了204例连续接受白血病(142例)、其他恶性肿瘤(5例)或再生障碍性贫血(57例)移植的尸检受者的肝脏组织学编码。27例白血病患者、2例癌症患者和3例再生障碍性贫血患者患有肝静脉闭塞病,移植后存活2 - 86天。早期病变表现为中央小静脉内膜下水肿和出血以及小叶中心充血伴肝细胞变性。后期病变表现为中央静脉管腔部分至完全纤维性闭塞以及小叶中心窦状隙纤维化。13例患者病程亚临床,19例有症状。肝静脉闭塞病在13例中危及生命或致命。典型症状在移植后1 - 3周出现,包括体重突然增加、肝脏肿大、腹水、高胆红素血症和脑病。统计分析显示,与白血病移植相关的肝静脉闭塞病患病率显著更高(P = 0.014),移植前采用更严格化疗放疗方案预处理的患者患病率更高(P < 0.001),预处理包括二甲磺酸丁酯的患者肝静脉闭塞病增加三至四倍(P < 0.005)。移植前肝功能检查异常在肝静脉闭塞病患者中也更常见。没有因素可预测已确诊肝静脉闭塞病的临床结局。即使在伴有严重门周肝炎和胆汁淤积的长期病例中,肝静脉闭塞病与肝移植物抗宿主病也无关联。23例患者发现有其他小叶中心病变(肝细胞变性、窦状隙纤维化和静脉硬化)。这些非特异性改变可能与病毒性肝炎、移植物抗宿主病或放化疗效应有关。